Abstract:Maria Paula Diaz Soto, 1 Joseph K Lim 2 1 Department of Medicine, Yale School of Medicine, New Haven, CT, USA; 2 Yale Liver Center and Section of Digestive Diseases, Yale School of Medicine, New Haven, CT, USA Correspondence: Joseph K Lim Professor of Medicine, Yale Liver Center and Section of Digestive Diseases, Yale School of Medicine, 333 Cedar Street, LMP 1080, New Haven, CT 06520-8019, USA Tel +1 (203) 737-6063 Fax +1 (203) 785-7273 Email Non-alcoholic steatohepatitis (NASH) is associated with significant morbidity and mortality due to liver cirrhosis, liver failure, and hepatocellular carcinoma, and represents a leading indication for liver transplantation in the United States (U.S.). A growing spectrum of novel therapies are currently in clinical development and target several mechanisms of action which address hepatic steatosis, steatohepatitis, and hepatic fibrosis. Cenicriviroc (Allergan, Dublin, Ireland) is a novel oral antagonist of CC-motif chemokine receptors 2 and 5 (CCR2/5) which have demonstrated expression on circulating monocytes and Kupffer cells. Preclinical models have confirmed that CCR2/5 antagonism may block fat accumulation and Kupffer cell activation and disrupt monocyte/macrophage recruitment and hepatic stellate cell activation responsible for fibrogenesis. Herein we review results from the phase 2b CENTAUR trial and study designs for the phase 2b TANDEM and phase 3 AURORA trials and discuss the potential role of cenicriviroc in future pharmacotherapy for NASH fibrosis. Keywords: cenicriviroc, fatty liver, non-alcoholic steatohepatitis, liver fibrosis, antifibrotic therapy, clinical trials Nonalcoholic steatohepatitis (NASH) is the inflammatory subtype of nonalcoholic fatty liver disease (NAFLD) and is characterized by steatosis, hepatocyte injury (ballooning) and inflammation, with or without fibrosis. 1 The presence of fibrosis increases the risk of disease progression to cirrhosis, end-stage liver disease, hepatocellular carcinoma and need for liver transplantation. 2,3 Notably, fibrosis severity is the only histologic feature of NASH independently associated with liver related and all-cause mortality. 4–6 Paralleling the epidemic of metabolic conditions such as obesity, type 2 diabetes mellitus, and dyslipidemia, the prevalence of NAFLD/NASH has been increasing over the past decade. 7 NASH-associated cirrhosis has become the leading indication for liver transplantation in women and is the second leading indication in men. 8 The global prevalence of NAFLD is estimated at approximately 25% of the world population, of whom 20% are expected to develop NASH. 7,9,10 There are currently no US Federal Drug Administration (FDA) approved therapies for the treatment of NASH, highlighting an important unmet medical need. The aim of this concise review is to explore the therapeutic potential of cenicriviroc by summarizing key results of major preclinical and clinical studies and discussing the future direction for cenicriviroc as a potential treatment for NASH. NASH is a complex entity in which numerous signaling pathways are involved in disease pathophysiology. Two specific pathways, macrophage-mediated inflammation and hepatic stellate cell activation, have been identified as key pathways in disease progression (Figure 1). 11 Accumulation of fat in the liver may be associated with inflammation and hepatic injury (ballooning), which in turn may activate hepatocytes, liver macrophages (Kupffer cells) and hepatic stellate cells (HSC) to release chemokines which interact with the CCR2 receptor on circulating monocytes to promote infiltration into the liver where they differentiate into pro-inflammatory macrophages. 12,13 This population of cells is referred to as monocyte-derived macrophages (MoMF) which are distinct from the tissue-resident macrophages, Kupffer cells (KC). 12,13 Both MoMF and KC release proinflammatory cytokines such as transforming growth factor β (TGF-β) and platelet-delivered growth factor (PDGF) which activates HSC. 14,15 Activated HSC differentiate into myofibroblast-like cells which produce collagen resulting in liver fibrosis. 16 The CCR5 chemokine receptor is also expressed in a subpopulation of lymphocytes and HCS and contributes to profibrogenic activation and proliferation. 17,18 Cenicriviroc (CVC), an oral dual CCR2/CCR5 antagonist is under investigation as a potential treatment for NASH due to its broad spectrum of anti-inflammatory and anti-fibrotic effects. 19 Figure 1 Cenicriviroc mechanism of action. Abbreviations: CCL-2, chemokine (C-C motif) ligand 2; CCR2, C-C chemokine receptor 2; TFGB, transforming growth factor β; PDGF, platelet- -Abstract Truncated-

Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study

Phase 2, open-label, rollover study of cenicriviroc for liver fibrosis associated with metabolic dysfunction–associated steatohepatitis

Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis

1848-P: Insulin Sensitivity and Metabolic Profile of Subjects with Type 2 Diabetes and Nonalcoholic Steatohepatitis after Exposure to Cenicriviroc: A Subanalysis of the CENTAUR Study

Evaluating the Therapeutic Potential of Cenicriviroc in the Treatment of Nonalcoholic Steatohepatitis with Fibrosis: A Brief Report on Emerging Data

Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet-induced mouse model of nonalcoholic steatohepatitis

Cenicriviroc Suppresses and Reverses Steatohepatitis by Regulating Macrophage Infiltration and M2 Polarization in Mice

The therapeutic potential of C-C chemokine receptor antagonists in nonalcoholic steatohepatitis

Tropifexor plus cenicriviroc combination versus monotherapy in non-alcoholic steatohepatitis: Results from the Phase 2b TANDEM study

Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis

BMS-986263 in patients with advanced hepatic fibrosis: 36-week results from a randomized, placebo-controlled phase 2 trial

Dual CCR2/CCR5 antagonism by Cenicriviroc efficiently inhibits both MCP-1 and RANTES induced chemokine receptor internalization in murine pro-inflammatory monocytes (CCR6P.221)

Pharmacological Inhibition of CCR2/5 Signaling Prevents and Reverses Alcohol-Induced Liver Damage, Steatosis, and Inflammation in Mice

C-C motif chemokine receptor 2 inhibition reduces liver fibrosis by restoring the immune cell landscape

The role of Ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review

Cenicriviroc, a cytokine receptor antagonist, potentiates all-trans retinoic acid in reducing liver injury in cholestatic rodents

Inhibition of intrahepatic monocyte recruitment by Cenicriviroc and extracellular matrix degradation by MMP1 synergistically attenuate liver inflammation and fibrogenesis in vivo

A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis

Multicenter, Double‐Blind, Randomized Trial of Emricasan in Hepatitis C–Treated Liver Transplant Recipients With Residual Fibrosis or Cirrhosis

Role of cenicriviroc in the management of nonalcoholic fatty liver disease

Time‐dependent improvement of liver inflammation, fibrosis and metabolic liver function after successful direct‐acting antiviral therapy of chronic hepatitis C